Cargando…

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA

BACKGROUND: Overactive bladder (OAB) is associated with considerable clinical and economic burden. Treatment of patients with OAB using anticholinergics is limited by tolerability issues and increased anticholinergic burden, which is associated with increased risk of dementia and falls/fractures. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jing Voon, Gahn, James C., Nesheim, Jeffrey, Mudd,, Paul N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522665/ https://www.ncbi.nlm.nih.gov/pubmed/35881325 http://dx.doi.org/10.1007/s40273-022-01163-5

Ejemplares similares

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
por: Weber, Michael A., et al.
Publicado: (2021)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Impact of overactive bladder on retrograde ejaculation
por: Salvarci, Ahmet, et al.
Publicado: (2018)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

USA laboratory: Budgets
Publicado: (1971)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Schooling impacts on the overactive bladder diagnosis in women
por: Ferreira, Larissa R., et al.
Publicado: (2017)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

USA laboratories budget situation
Publicado: (1970)

The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder
por: Gurocak, Serhat, et al.
Publicado: (2015)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Oxybutynin topical gel in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2010)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Intravesical electrical stimulation treatment for overactive bladder: An observational study
por: Yune, J. Joshua, et al.
Publicado: (2018)

Clustering of patients with overactive bladder syndrome
por: Gross, James, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mr44kcstbk5ulev1njhcdg2rur